Drug Development

Protocols: Indivior claims PhIII success, points to 2017 FDA OK; InVivo touts another patient response in spinal study

The UK’s Indivior (LON: INDV) got a boost today after announcing that its Phase III study of a monthly dose of buprenorphine was positive. The biotech says that based on its conversations with the FDA, the company may get a green light for this therapy by the end of next year. The monthly dosing is intended to assist patients who are being treated for opioid abuse, making a relapse less likely.

Cambridge, MA-based InVivo Therapeutics’ stock $NVIV got a boost on its latest release touting the 5th case where its implant of the Neuro-Spinal Scaffold was linked to an upgrade in a patient’s condition. The 9th patient implanted was upgraded from a complete spinal cord injury to an incomplete injury. Its shares jumped 10%.

New York-based Rasna Therapeutics has executed a reverse merger, landing on the OTC exchange. The little biotech is working on new therapies for leukemia.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Regulatory Convergence 2017